Maze Therapeutics, Inc.
MAZENasdaq
$28.12
↑ +3.5%Jul 17 close · end-of-day
Price
1Y↑ +72.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.5B
Enterprise Value
$1.2B
P/E
—
P/S
—
P/B
4.4
EV/EBITDA
—
PEG
—
FCF Yield
-8.1%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$122.5M
Free Cash Flow (TTM)
-$122.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.9%
ROIC
-376.2%
Debt / Equity
0.1
Net Cash
$313.5M
Return 1Y
+64.8%
Company profile
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.
- CEO
- Jason Coloma
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 121
- Headquarters
- California
- Website
- mazetx.com
Management & directors
- Bernstein HaroldPresident, R&D & CMO
- Coloma Jason VChief Executive Officer
- Dandekar AtulCSBO
- Bachrodt AmySVP, Finance
Roles derived from SEC Form 4 filings.
Earnings
MAZE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.0M—
Diluted EPS-$0.45↓ -60.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $167.5M | — |
| Gross profit | — | — |
| Operating income | $57.6M | -$142.9M |
| Net income | $52.2M | -$131.1M |
| Diluted EPS | $1.25 | -$3.05 |
| Operating cash flow | $76.0M | -$111.9M |
| Free cash flow | $74.8M | -$112.7M |
| Gross margin | — | — |
| Operating margin | 34.4% | — |
| Net margin | 31.2% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $165.0M | $2.5M | — | — | $0.00 | — | — | $20.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $139.6M | -$24.2M | -$29.7M | -$35.4M | -$36.5M | -$33.0M | -$38.1M | -$26.6M |
| Net income | $139.1M | -$24.8M | -$29.6M | -$32.8M | -$33.7M | -$30.1M | -$34.6M | -$24.2M |
| Diluted EPS | $3.22 | -$10.25 | $22.19 | -$1.15 | -$0.77 | -$0.66 | -$0.47 | -$0.45 |
| Operating cash flow | $145.0M | -$23.2M | -$22.5M | -$29.5M | -$30.1M | -$24.6M | -$27.7M | -$39.1M |
| Free cash flow | $144.9M | -$23.3M | -$23.1M | -$29.8M | -$30.4M | -$24.7M | -$27.8M | -$39.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 84.6% | -969.2% | — | — | — | — | — | -132.8% |
| Net margin | 84.3% | -990.1% | — | — | — | — | — | -121.0% |
Company news
Jun 29, 2026
Jun 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Coloma Jason V· Chief Executive Officer | Sale | 30,311 | $29.95 | $907,920.54 | filing |
| 2026-07-01 | Bernstein Harold· President, R&D & CMO | Sale | 13,409 | $29.87 | $400,459.79 | filing |
| 2026-07-01 | Bernstein Harold· President, R&D & CMO | Option exercise | 14,609 | $10.42 | $152,225.78 | filing |
| 2026-07-01 | Coloma Jason V· Chief Executive Officer | Sale | 2,593 | $29.98 | $77,726.21 | filing |
| 2026-07-01 | Coloma Jason V· Chief Executive Officer | Sale | 1,597 | $30.44 | $48,606.13 | filing |
| 2026-07-01 | Bernstein Harold· President, R&D & CMO | Sale | 1,200 | $30.34 | $36,404.28 | filing |
| 2026-06-29 | Dandekar Atul· CSBO | Sale | 7,500 | $28.02 | $210,150.00 | filing |
| 2026-06-29 | Dandekar Atul· CSBO | Option exercise | 7,500 | $10.42 | $78,150.00 | filing |
| 2026-06-23 | Coloma Jason V· Chief Executive Officer | Sale | 23,865 | $26.05 | $621,673.70 | filing |
| 2026-06-22 | Coloma Jason V· Chief Executive Officer | Sale | 2,040 | $26.00 | $53,040.00 | filing |
| 2026-06-22 | Coloma Jason V· Chief Executive Officer | Sale | 1,953 | $26.00 | $50,780.93 | filing |
| 2026-06-01 | Bernstein Harold· President, R&D & CMO | Sale | 13,253 | $25.57 | $338,940.17 | filing |
| 2026-06-01 | Coloma Jason V· Chief Executive Officer | Sale | 6,090 | $26.20 | $159,536.69 | filing |
| 2026-06-01 | Bernstein Harold· President, R&D & CMO | Option exercise | 14,853 | $10.42 | $154,768.26 | filing |
| 2026-06-01 | Bernstein Harold· President, R&D & CMO | Sale | 1,600 | $26.36 | $42,172.16 | filing |
| 2026-06-01 | Coloma Jason V· Chief Executive Officer | Sale | 553 | $26.24 | $14,511.38 | filing |
| 2026-05-29 | Dandekar Atul· CSBO | Sale | 7,500 | $26.34 | $197,553.75 | filing |
| 2026-05-29 | Dandekar Atul· CSBO | Option exercise | 7,500 | $10.42 | $78,150.00 | filing |
| 2026-05-26 | Coloma Jason V· Chief Executive Officer | Sale | 25,582 | $26.02 | $665,515.73 | filing |
| 2026-05-22 | Coloma Jason V· Chief Executive Officer | Sale | 4,504 | $26.00 | $117,104.45 | filing |
| 2026-05-22 | Coloma Jason V· Chief Executive Officer | Sale | 2,478 | $26.00 | $64,428.00 | filing |
| 2026-05-15 | Coloma Jason V· Chief Executive Officer | Sale | 1,822 | $26.00 | $47,372.00 | filing |
| 2026-05-15 | Coloma Jason V· Chief Executive Officer | Sale | 116 | $26.00 | $3,016.00 | filing |
| 2026-05-14 | Bernstein Harold· President, R&D & CMO | Sale | 15,000 | $26.22 | $393,354.00 | filing |
| 2026-05-14 | Bernstein Harold· President, R&D & CMO | Option exercise | 15,000 | $10.42 | $156,300.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.